Retatrutide is not the only next-gen weight-loss drug in the pipeline. Several others aim at similar targets — some dual agonists, some amylin analogs, some legacy molecules finding new uses. Here's the field in 2026.
The field
| Drug | Class | Weight loss (trial) | FDA status | Timeline |
|---|---|---|---|---|
| Retatrutide | GLP-1 + GIP + glucagon (triple) | 24.2% @ 48w | Phase 3 | 2027+ |
| Tirzepatide | GLP-1 + GIP (dual) | 22.5% @ 72w | Approved | Now |
| Semaglutide | GLP-1 (single) | 14.9% @ 68w | Approved | Now |
| CagriSema | GLP-1 + amylin | 22.7% @ 68w | Phase 3 | 2026–2027 |
| Mazdutide | GLP-1 + glucagon (dual) | 14.4% @ 48w | Phase 3 / CN approved | 2027+ US |
| Survodutide | GLP-1 + glucagon (dual) | 18.7% @ 46w | Phase 3 | 2027+ |
| Orforglipron | GLP-1 (oral, small-molecule) | 14.7% @ 36w | Phase 3 | 2026 |
| Tesamorelin | GHRH analog | Visceral-fat specific | HIV lipodystrophy only | Now (narrow) |
Retatrutide vs Zepbound / Mounjaro
Zepbound and Mounjaro are both tirzepatide — the same active drug, different branded indications. Covered in full in our vs tirzepatide comparison.
Retatrutide vs Mazdutide
Mazdutide (IBI362) is a GLP-1/glucagon dual agonist, developed by Innovent in China in partnership with Eli Lilly. Approved in China for obesity in mid-2025. Weight loss in the GLORY-1 Chinese Phase 3 trial: 14.4% at 48 weeks on 9 mg.
Mazdutide differs from retatrutide primarily by lacking GIP activation. The clinical implication: less appetite suppression, modestly less weight loss, similar liver-fat effects. Mazdutide will likely not reach US approval before 2027 — Innovent and Lilly haven't filed a US BLA.
Retatrutide vs Survodutide
Survodutide (BI 456906) is a GLP-1/glucagon dual agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. Phase 2 showed 18.7% weight loss at 46 weeks on the 4.8 mg dose. Phase 3 is ongoing.
Mechanistically similar to mazdutide (same dual-target profile). Survodutide's Phase 2 results were stronger than mazdutide's, which analysts have attributed to dose range and titration strategy. Both will face the same competitive pressure from retatrutide and tirzepatide.
Retatrutide vs Cagrilintide (CagriSema)
Cagrilintide is Novo Nordisk's long-acting amylin analog. On its own, it produces modest weight loss (~8–10%). Combined with semaglutide as CagriSema, it approaches tirzepatide-level weight loss (22.7%). Phase 3 REDEFINE trials are ongoing.
Mechanistically, amylin works differently from the incretin axis — it affects satiety via a distinct CNS pathway. This is why combining it with a GLP-1 amplifies the effect. Cagrilintide alone isn't going to replace retatrutide, but CagriSema is a real competitor, likely reaching market slightly before retatrutide (projection: late 2026–2027).
Retatrutide vs Tesamorelin
Tesamorelin (Egrifta, Theratechnologies) is a growth hormone–releasing hormone analog, FDA-approved only for HIV-associated visceral lipodystrophy. It is not a weight-loss drug — it reduces visceral fat specifically in HIV patients. Pricing is extreme ($3,000+/mo cash).
Comparison to retatrutide is largely academic. Different mechanism, different indication, different patient population. The query "tesamorelin vs retatrutide" mostly comes from the peptide community exploring body-recomposition stacks — but neither drug is appropriate for that use case.
Retatrutide and tirzepatide taken together — why people ask
The peptide community has experimented with tirzepatide + retatrutide stacks on the theory that redundant GLP-1 activation plus the unique glucagon activity could push weight loss further. This is not evidence-based. Both drugs saturate the GLP-1 receptor; adding the second dose compounds GI side effects without added benefit. If you're plateaued on tirzepatide, waiting for retatrutide approval is the supported path.
The decision matrix in plain English
- Available now, best proven efficacy: tirzepatide (Zepbound).
- Available now, longest safety record: semaglutide (Wegovy / Ozempic).
- Best projected efficacy, still in trials: retatrutide.
- CagriSema if it arrives first: tirzepatide-like weight loss, different mechanism, could be second-tier choice.
- Everything else (mazdutide, survodutide, tesamorelin): niche or far from US market. Don't wait for them.